Nedisertib Drug Asset Due Diligence Report 2026

This Nedisertib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Nedisertib can convert its Small molecule drug profile and PRKDC biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Nedisertib (query alias: Nedisertib)
Modality / target	Small molecule drug; PRKDC; PRKDC inhibitors
Highest global status	Phase 2
Originator	Merck Serono SA
Active developers	Merck Serono SA

The MCP disease footprint includes Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05868174	Phase 1	Recruiting	36	Primary endpoint not disclosed in English source
NCT05711615	Phase 1	Recruiting	30	Primary endpoint not disclosed in English source
NCT05687136	Phase 1	Recruiting	66	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A phase 1 trial of M3814 (peposertib) in combination with lutetium 177 DOTATATE for metastatic well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Phase 1; n=27; evaluation: Positive. Reported fields: DLT = No dose limiting toxicities (DLTs) were reported at dose level 2.

DNAR-08. Phase I Trial of Peposertib (DNA-PK inhibitor) Plus Radiation in Newly Diagnosed MGMT-Unmethylated Glioblastoma, Updated Clinical, Radiographic, and Biomarker Outcomes

Phase 1; n=21; evaluation: Positive. Reported fields: FTB = In 9 patients with available DSC-MRI, FTB map analysis showed a trend toward increased treatment-effect volume at 4 weeks post-RT compared to immediate post-RT (median +9.4%, p = 0.195).

A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase l results.

Phase 1/2; n=15; evaluation: Positive. Reported fields: Adverse Event: anemia = 1 patient experienced anemia ; Adverse Event: anemia = 1 patient experienced anemia

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Nedisertib addresses Small Cell Lung Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “target-level comparable: PRKDC.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PRKDC records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2017-01-11	Merck KGaA has paid Vertex Pharmaceuticals $230 million upfront for the rights to four cancer programs.	Phase 2	US$230.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Her2-binding molecules”. The milestone feed surfaced a patent-application signal described as “Methods and compositions for the treatment of cancer using an inhibitor of PRM t5”. The milestone feed surfaced a patent-application signal described as “Combination therapy for treating abnormal cell growth”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO